Celgene Risk Management: Understanding REMS Programs

Understanding risk management for certain medications is crucial for patient safety. Celgene, now part of Bristol Myers Squibb, has implemented comprehensive Risk Evaluation and Mitigation Strategies (REMS) for specific therapies. These programs are designed to minimize serious risks associated with potent drugs like lenalidomide (Revlimid®), pomalidomide (Pomalyst®), and thalidomide (Thalomid®), particularly their potential for severe birth defects. This guide provides essential information on Celgene's approach to medication safety, ensuring that the benefits of these treatments continue to outweigh their risks. These specialized programs involve prescribers, pharmacists, and patients, establishing clear guidelines for prescribing, dispensing, and taking medications. The goal is to educate all parties involved about potential hazards and the steps necessary to mitigate them, thereby protecting patients and promoting responsible medication use. Each REMS program aims to prevent severe outcomes like embryo-fetal exposure, which is a primary concern for these specific drugs.

Enrolling in Celgene's Medication Safety Programs

• Prescriber Certification: Healthcare providers must enroll and become certified with the specific REMS program to legally prescribe the medication. This often includes completing training and agreeing to comply with all program requirements.
• Patient Enrollment: Patients must be enrolled in the REMS program and agree to follow all its conditions. This includes signing a Patient-Physician Agreement Form and actively participating in required monitoring.
• Pharmacy Certification: Pharmacies must be certified with the REMS program to dispense the medication. They are responsible for ensuring that all dispensing requirements are met before providing the drug to the patient.
• Contraception and Pregnancy Testing: For females of reproductive potential, rigorous pregnancy testing and the use of two acceptable forms of contraception are mandatory before, during, and for a specified period after treatment. Male patients must also adhere to contraception requirements and not donate sperm.
• Patient Counseling: Both prescribers and pharmacists are required to counsel patients thoroughly on the benefits, serious risks, and safe-use conditions of the medication.

Accessing Your Celgene REMS Account for Compliance

1. For Prescribers: To manage your certification and patient enrollments, you will typically access an online digital portal. This involves completing a Prescriber Enrollment Form and submitting required documentation. Many tasks, such as obtaining prescription authorization numbers and completing prescriber surveys, can be done via this online system or through an automated phone system.
2. For Patients: Access to program-specific patient resources and mandatory confidential surveys is often available through dedicated websites or mobile applications, like the REMS Companion App. You might need to provide personal identifiers or prescription details to verify your enrollment and complete surveys. Follow instructions provided by your healthcare team to access these platforms.
3. For Pharmacists: Certified pharmacies often have access to an online pharmacy portal to obtain confirmation numbers before dispensing medication and to manage program compliance. Check with the specific REMS program for details on how to register and access these online tools.

Core Safety Commitments of Celgene's REMS Initiatives

• Restricted Distribution System: Medications are only available through certified prescribers and pharmacies, ensuring tight control over who receives the drug.
• Mandatory Education: Comprehensive educational materials are provided to prescribers, pharmacists, and patients to ensure a deep understanding of the drug’s risks and safe handling practices.
• Patient-Physician Agreement: Patients sign a formal agreement, confirming their understanding of the risks and their commitment to follow program rules, especially contraception guidelines.
• Regular Monitoring and Surveys: Patients and prescribers complete mandatory confidential surveys (e.g., KAB surveys) at regular intervals to assess comprehension of safe-use messages and compliance with program requirements.
• Pregnancy Exposure Registries: Dedicated registries monitor pregnancy outcomes in cases of accidental exposure, helping to further understand and mitigate risks.
• Authorization Numbers: Prescribers must obtain a unique authorization number for each prescription, which pharmacies then verify before dispensing the medication.

Navigating Challenges in Your Celgene REMS Participation

Securing Patient Information in Celgene REMS

• 🔒 Protect Your Login Information: Always use strong, unique passwords for any online accounts related to the REMS program. Never share your login credentials with anyone.
• 🔒 Maintain Confidentiality: Patient health information and program data are highly sensitive. Ensure all forms and surveys are completed in a private and secure environment.
• 🔒 Report Suspicious Activity: If you notice any unusual activity related to your REMS account or suspect a data breach, report it immediately to the REMS Call Center and your healthcare provider.
• 🔒 Handle Medications Safely: Adhere strictly to the storage and disposal instructions for REMS medications to prevent accidental exposure, especially to those for whom the drug is contraindicated.

Clarifying Your Questions on Celgene REMS